All Title Author
Keywords Abstract

Escin Chemosensitizes Human Pancreatic Cancer Cells and Inhibits the Nuclear Factor-kappaB Signaling Pathway

DOI: 10.1155/2013/251752

Full-Text   Cite this paper   Add to My Lib


Background. There is an urgent need to develop new treatment strategies and drugs for pancreatic cancer that is highly resistant to radio-chemotherapy. Aesculus hippocastanum (the horse chestnut) known in Chinese medicine as a plant with anti-inflammatory, antiedema, antianalgesic, and antipyretic activities. The main active compound of this plant is Escin (C54H84O23). Objective. To evaluate the effect of Escin alone and combined with chemotherapy on pancreatic cancer cell survival and to unravel mechanism(s) of Escin anticancer activity. Methods. Cell survival was measured by XTT colorimetric assay. Synergistic effect of combined therapy was determined by CalcuSyn software. Cell cycle and induction of apoptosis were evaluated by FACS analysis. Expression of NF-κB-related proteins (p65, IκB , and p-IκB ) and cyclin D was evaluated by western blot analysis. Results. Escin decreased the survival of pancreatic cancer cells with IC50 = 10–20?M. Escin combined with gemcitabine showed only additive effect, while its combination with cisplatin resulted in a significant synergistic cytotoxic effect in Panc-1 cells. High concentrations of Escin induced apoptosis and decreased NF-κB-related proteins and cyclin D expression. Conclusions. Escin decreased pancreatic cancer cell survival, induced apoptosis, and downregulated NF-κB signaling pathway. Moreover, Escin sensitized pancreatic cancer cells to chemotherapy. Further translational research is required. 1. Introduction Pancreatic cancer is considered to be one of the most aggressive forms of human cancers. It is the fourth leading cause of cancer deaths in the United States, its median survival rate is 4–6 months, and the overall 5-year survival rate is only 6% [1, 2]. Moreover, it is highly resistant to apoptosis-inducing therapy, such as radio- and chemotherapy [3, 4]. Thus, there is an urgent need to develop new treatment strategies in order to reduce the high mortality rates of these patients. According to ethnobotany pharmacopeia, active compounds of many plants are used for medical needs and provide additional therapeutic effects to modern medicine. One meta-analysis of drugs that were developed between 1981 and 2001 revealed that natural products constitute a significant percentage of those drugs [5]. Many antitumor agents that are now in clinical oncology practice are of natural origin, such as taxanes (docetaxel, paclitaxel), Vinca alkaloids (vindesine, vinblastine, vincristine), and anthracyclines (idarubicin, daunorubicin, epirubicin), indicating a promising future in the use of natural products from


[1]  A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010.
[2]  P. E. Oberstein and K. P. Olive, “Pancreatic cancer: why is it so hard to treat?” Therapeutic Advances in Gastroenterology, vol. 6, no. 4, pp. 321–337, 2013.
[3]  V. Heinemann, “Present and future treatment of pancreatic cancer,” Seminars in Oncology, vol. 29, no. 3, supplement 9, pp. 23–31, 2002.
[4]  H. Cao, L. E. D, and L. X. Yang, “Current status in chemotherapy for advanced pancreatic adenocarcinoma,” Anticancer Research, vol. 33, no. 5, pp. 1785–1791, 2013.
[5]  D. J. Newman, G. M. Cragg, and K. M. Snader, “Natural products as sources of new drugs over the period 1981–2002,” Journal of Natural Products, vol. 66, no. 7, pp. 1022–1037, 2003.
[6]  L. Berkovich, I. Ron, G. Earon, S. Abu-Ghanem, A. Rimmon, and S. Lev-Ari, “The role of medicinal herbs with anti-inflammatory properties in prevention and treatment of cancer,” Harefuah, vol. 151, no. 11, pp. 629–632, 2012.
[7]  S. Lev-Ari, L. Strier, D. Kazanov et al., “Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells,” Clinical Cancer Research, vol. 11, no. 18, pp. 6738–6744, 2005.
[8]  S. Lev-Ari, L. Strier, D. Kazanov et al., “Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells,” Rheumatology, vol. 45, no. 2, pp. 171–177, 2006.
[9]  S. Lev-Ari, A. Vexler, A. Starr et al., “Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines,” Cancer Investigation, vol. 25, no. 6, pp. 411–418, 2007.
[10]  L. Berkovich, G. Earon, I. Ron, A. Rimmon, A. Vexler, and S. Lev-Ari, “Moringa Oleifera down-regulates NF-kB and increases cytotoxic effects of chemotherapy in pancreatic cancer cells,” BMC Complementary and Alternative Medicine, vol. 13, no. 1, article 212, 2013.
[11]  J. Jiang, I. Eliaz, and D. Silva, “Synergistic and additive effects of modified citrus pectin with two polybotanical compounds, in the suppression of invasive behavior of human breast and prostate cancer cells,” Integrative Cancer Therapies, vol. 12, no. 2, pp. 145–152, 2013.
[12]  J. Jiang, I. Eliaz, and D. Sliva, “Suppression of growth and invasive behavior of human prostate cancer cells by ProstaCaid?: mechanism of activity,” International Journal of Oncology, vol. 38, no. 6, pp. 1675–1682, 2011.
[13]  H. Matsuda, Y. Li, and M. Yoshikawa, “Effects of escins Ia, Ib, IIa, and IIb from horse chestnuts on gastrointestinal transit and ileus in mice,” Bioorganic and Medicinal Chemistry, vol. 7, no. 8, pp. 1737–1741, 1999.
[14]  M. Rothkopf and G. Vogel, “New findings on the efficacy and mode of action of the horse chestnut saponin escin,” Arzneimittel-Forschung, vol. 26, no. 2, pp. 225–235, 1976.
[15]  J. M. R. Patlolla, J. Raju, M. V. Swamy, and C. V. Rao, “β-Escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21waf1/cip1 in colon cancer cells,” Molecular Cancer Therapeutics, vol. 5, no. 6, pp. 1459–1466, 2006.
[16]  Z. Zhang, J. Gao, X. Cai et al., “Escin sodium induces apoptosis of human acute leukemia Jurkat T cells,” Phytotherapy Research, vol. 25, no. 12, pp. 1747–1755, 2011.
[17]  G. Güney, H. M. Kutlu, and A. ??can, “The apoptotic effects of Escin in H-Ras transformed 5RP7 cell line,” Phytotherapy Research, vol. 27, no. 6, pp. 900–905, 2013.
[18]  D.-Y. Shen, J.-H. Kang, W. Song et al., “Apoptosis of human cholangiocarcinoma cell lines induced by β-escin through mitochondrial caspase-dependent pathway,” Phytotherapy Research, vol. 25, no. 10, pp. 1519–1526, 2011.
[19]  F. Grases, R. Garca-Gonzlez, E. Redondo et al., “Effects of escin on indinavir crystallization time in the urine of patients with HIV-I infection: a multicenter, randomized, open-label, controlled, four-period crossover trial,” Clinical Therapeutics, vol. 26, no. 12, pp. 2045–2055, 2004.
[20]  D. Wetzel, W. Menke, R. Dieter, V. Smasal, B. Giannetti, and M. Bulitta, “Escin/diethylammonium salicylate/heparin combination gels for the topical treatmentof acute impact injuries: a randomised, double blind, placebo controlled, multicentre study,” British Journal of Sports Medicine, vol. 36, no. 3, pp. 183–188, 2002.
[21]  F.-L. Li, R. Xu, R. Zhou et al., “Clinical effect of escin on patients with cutaneous pruritus caused by blood stasis and wind-dryness,” Zhong Xi Yi Jie He Xue Bao, vol. 2, no. 6, pp. 426–428, 2004.
[22]  S. C. Gupta, J. H. Kim, S. Prasad, and B. B. Aggarwal, “Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals,” Cancer and Metastasis Reviews, vol. 29, no. 3, pp. 405–434, 2010.
[23]  W. Yang, J. Zhao, Y. X. Cui et al., “Anti-HIV-1 protease triterpenoid saponins from the seeds of Aesculuschinensis,” Journal of Natural Products, vol. 62, pp. 1503–1510, 1999.
[24]  J.-N. Hu, X.-M. Zhu, L.-K. Han et al., “Anti-obesity effects of escins extracted from the seeds of Aesculus turbinata Blume (Hippocastanaceae),” Chemical and Pharmaceutical Bulletin, vol. 56, no. 1, pp. 12–16, 2008.
[25]  T. Arnould, D. Janssens, and C. Michiels, “Effect of aescine on hypoxia-induced activation of human endothelial cells,” European Journal of Pharmacology, vol. 315, no. 2, pp. 227–233, 1996.
[26]  S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, inflammation, and cancer,” Cell, vol. 140, no. 6, pp. 883–899, 2010.
[27]  S. Liptay, C. K. Weber, L. Ludwig, M. Wagner, G. Adler, and R. M. Schmid, “Mitogenic and antiapoptotic role of constitutive NF-κB/Rel activity in pancreatic cancer,” International Journal of Cancer, vol. 105, no. 6, pp. 735–746, 2003.
[28]  B. B. Aggarwal, “Nuclear factor-κB: the enemy within,” Cancer Cell, vol. 6, no. 3, pp. 203–208, 2004.
[29]  A. Arlt, A. Gehrz, S. Müerk?ster et al., “Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death,” Oncogene, vol. 22, no. 21, pp. 3243–3251, 2003.
[30]  H.-M. Shen and V. Tergaonkar, “NFκB signaling in carcinogenesis and as a potential molecular target for cancer therapy,” Apoptosis, vol. 14, no. 4, pp. 348–363, 2009.
[31]  K. B. Harikumar, B. Sung, M. K. Pandey, S. Guha, S. Krishnan, and B. B. Aggarwal, “Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-κB signaling pathway,” Molecular Pharmacology, vol. 77, no. 5, pp. 818–827, 2010.
[32]  T.-C. Chou and P. Talalay, “Analysis of combined drug effects: a new look at a very old problem,” Trends in Pharmacological Sciences, vol. 4, pp. 450–454, 1983.
[33]  X.-Y. Zhou, F.-H. Fu, Z. Li, Q.-J. Dong, J. He, and C.-H. Wang, “Escin, a natural mixture of triterpene saponins, exhibits antitumor activity against hepatocellular Carcinoma,” Planta Medica, vol. 75, no. 15, pp. 1580–1585, 2009.
[34]  L. Li, B. B. Aggarwal, S. Shishodia, J. Abbruzzese, and R. Kurzrock, “Nuclear factor-κB and IκB are constitutively active in human pancreatic cells, and their down-regulation by curcumin (Diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis,” Cancer, vol. 101, no. 10, pp. 2351–2362, 2004.
[35]  H.-S. Shiah, W. Gao, D. C. Baker, and Y.-C. Cheng, “Inhibition of cell growth and nuclear factor-κB activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503,” Molecular Cancer Therapeutics, vol. 5, no. 10, pp. 2484–2493, 2006.
[36]  Y. W. Wang, S. J. Wang, Y. N. Zhou, S. H. Pan, and B. Sun, “Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo,” Journal of Cancer Research and Clinical Oncology, vol. 138, no. 5, pp. 785–797, 2012.
[37]  Q. Liu, W. T. Y. Loo, S. C. W. Sze, and Y. Tong, “Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation of NFκB, cyclinD and MMP-1 transcription,” Phytomedicine, vol. 16, no. 10, pp. 916–922, 2009.
[38]  S. Shishodia, S. Majumdar, S. Banerjee, and B. B. Aggarwal, “Ursolic acid inhibits nuclear factor-κB activation induced by carcinogenic agents through suppression of IκBα kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1,” Cancer Research, vol. 63, no. 15, pp. 4375–4383, 2003.
[39]  N. Radulovich, N.-A. Pham, D. Strumpf et al., “Differential roles of cyclin D1 and D3 in pancreatic ductal adenocarcinoma,” Molecular Cancer, vol. 9, article 24, 2010.
[40]  I. Jutooru, G. Chadalapaka, P. Lei, and S. Safe, “Inhibition of NFκB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation,” The Journal of Biological Chemistry, vol. 285, no. 33, pp. 25332–25344, 2010.
[41]  X.-Z. Cai, J. Wang, X.-D. Li et al., “Curcumin suppresses proliferation and invasion in human gastric cancer cells by downregulation of PAK1 activity and cyclin D1 expression,” Cancer Biology & Therapy, vol. 8, no. 14, pp. 1360–1368, 2009.
[42]  C. Ramachandran, A. Resek, E. Esclon, A. Aviram, and S. Melmick, “Potention of gemcitabine by TumericForce in pancreatic cancer cell lines,” Oncology Reports, vol. 23, pp. 1529–1535, 2010.
[43]  B. Holcomb, M. Yip-Schneider, and C. M. Schmidt, “The role of nuclear factor κB in pancreatic cancer and the clinical applications of targeted therapy,” Pancreas, vol. 36, no. 3, pp. 225–235, 2008.
[44]  S. Sebens, A. Arlt, and H. Sch?fer, “NF-kappaB as a molecular target in the therapy of pancreatic carcinoma,” Recent Results in Cancer Research, vol. 177, pp. 151–164, 2008.
[45]  A. Arlt and C. Schafer, “NFκB-dependent chemoresistance,” The International Journal of Clinical Pharmacology and Therapeutics, vol. 40, pp. 336–347, 2002.
[46]  K. B. Harikumar, B. Sung, S. T. Tharakan et al., “Sesamin manifests chemopreventive effects through the suppression of NF-κB-regulated cell survival, proliferation, invasion, and angiogenic gene products,” Molecular Cancer Research, vol. 8, no. 5, pp. 751–761, 2010.
[47]  H. A. Burris III, M. J. Moore, J. Andersen et al., “Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: A randomized trial,” Journal of Clinical Oncology, vol. 15, no. 6, pp. 2403–2413, 1997.
[48]  V. Heinemann, H. Wilke, H.-G. Mergenthaler et al., “Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer,” Annals of Oncology, vol. 11, no. 11, pp. 1399–1403, 2000.
[49]  S. Banerjee, Z. Wang, D. Kong, and F. H. Sarkar, “3,3′-diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer,” Cancer Research, vol. 69, no. 13, pp. 5592–5600, 2009.
[50]  S. C. Gupta, R. Kannappan, S. Reuter, J. H. Kim, and B. B. Aggarwal, “Chemosensitization of tumors by resveratrol,” Annals of the New York Academy of Sciences, vol. 1215, no. 1, pp. 150–160, 2011.


comments powered by Disqus